Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Cancer Vaccines

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...

Vaccine Production

Vaccine Production

Vaccine production involves a sequence of upstream and downstream processes to generate a safe and effective immunological product. It begins with cultivating microorganisms, such as viruses or bacteria, to obtain antigenic material. For viral vaccines, mammalian host cells are grown in bioreactors and subsequently infected with the target virus. The virus replicates within the host cells, which are lysed to release viral particles. This lysate is then clarified through filtration or...

Vaccines

Vaccines

Vaccines are among the most effective tools in preventive medicine, designed to prepare the immune system to recognize and combat infectious agents. By introducing antigens—substances that the immune system identifies as foreign—vaccines stimulate an adaptive immune response that leads to immunological memory. This immunological memory enables the body to mount a faster and more effective response upon future exposures to the actual pathogen.Vaccines can be categorized based on the type of...

Preclinical Development: Overview

Preclinical Development: Overview

Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...

Clinical Trials: Overview

Clinical Trials: Overview

Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...

Vaccinations

Vaccinations

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Respiratory Nurse Leadership Requires Increased Profile, Role Clarity and Stronger Career Pathways: Binational Delphi Consensus Process and TSANZ Position Statement.

Respirology (Carlton, Vic.)·2025

Same author

Low-dose CT for lung cancer screening in a high-risk population (SUMMIT): a prospective, longitudinal cohort study.

The Lancet. Oncology·2025

Same author

Nanopore molecular trajectories of a eukaryotic reverse transcriptase reveal a long-range RNA structure sensing mechanism.

bioRxiv : the preprint server for biology·2023

Same author

prM-reactive antibodies reveal a role for partially mature virions in dengue virus pathogenesis.

Proceedings of the National Academy of Sciences of the United States of America·2023

Same author

Solid Phase Synthesis of DNA Nanostructures in Heavy Liquid.

Small (Weinheim an der Bergstrasse, Germany)·2022

Same author

Stochastic modeling of antibody binding predicts programmable migration on antigen patterns.

Nature computational science·2022

Search research articles

Related Experiment Video

Updated: Jul 20, 2026

Chromogenic In Situ Hybridization as a Tool for HPV-Related Head and Neck Cancer Diagnosis

Chromogenic In Situ Hybridization as a Tool for HPV-Related Head and Neck Cancer Diagnosis

Published on: June 14, 2019

Chapter 11: HPV vaccines: commercial research & development.

Stephen Inglis¹, Alan Shaw, Scott Koenig

¹National Institute for Biological Standards and Control, South Mimms, Potters Bar, Hertfordshire, UK. singlis@nibsc.ac.uk

|September 5, 2006

Summary

Two promising human papillomavirus (HPV) vaccines are nearing completion thanks to significant industrial commitment. This review details the commercial considerations and R&D challenges in developing these vital HPV vaccines.

More Related Videos

Use of Interferon-γ Enzyme-linked Immunospot Assay to Characterize Novel T-cell Epitopes of Human Papillomavirus

Use of Interferon-γ Enzyme-linked Immunospot Assay to Characterize Novel T-cell Epitopes of Human Papillomavirus

Published on: March 8, 2012

Related Experiment Videos

Last Updated: Jul 20, 2026

Chromogenic In Situ Hybridization as a Tool for HPV-Related Head and Neck Cancer Diagnosis

Chromogenic In Situ Hybridization as a Tool for HPV-Related Head and Neck Cancer Diagnosis

Published on: June 14, 2019

Use of Interferon-γ Enzyme-linked Immunospot Assay to Characterize Novel T-cell Epitopes of Human Papillomavirus

Use of Interferon-γ Enzyme-linked Immunospot Assay to Characterize Novel T-cell Epitopes of Human Papillomavirus

Published on: March 8, 2012

Area of Science:

Vaccinology
Oncology
Public Health

Background:

The development of prophylactic vaccines against human papillomavirus (HPV) represents a significant advancement in cancer prevention.
Two major pharmaceutical companies, Merck & Co., Inc. and GlaxoSmithKline (GSK), have independently pursued the development of HPV vaccines.

Observation:

The industrial perspective on vaccine development is crucial for understanding the journey of these promising HPV vaccines.
Significant financial and research commitments were made by manufacturers over a decade, despite the absence of guaranteed success.

Findings:

This chapter examines the key commercial considerations and research and development hurdles faced during the development of two distinct HPV prophylactic vaccines.
Both Merck and GSK navigated complex challenges to bring their HPV vaccines to advanced clinical development, demonstrating efficacy and progressing towards licensing.

Implications:

The successful development of these HPV vaccines highlights the importance of sustained industrial investment in public health initiatives.
Understanding the industrial R&D process provides valuable insights for future vaccine development programs, particularly for diseases with long development cycles.
The availability of effective HPV vaccines has the potential to dramatically reduce the incidence of HPV-related cancers globally.